Table 2.

Comparison of tumor characteristics in different regions is shown in pre-drug treated tumor^@ and post-treated tumor^# by sodium MRI image intensity and histology, histo-immunology parameters as shown in Figures 5 and 6. By using eyepiece-micrometer square counter (100 squares per high power field), necrosis*(<25% cells in micrometer square), viable cells**(<60% cells in micrometer square) and apoptosis*** (20–40 apoptotic nuclei in HPF) and cyst space****(<100 μm) per HPF were premalignant histology characteristics. IC/EC space (% space in HPF), necrosis, viable cells are shown as number of micrometer squares with <25% necrosis area in HPF by histology. Apoptotic index (A.I.) and proliferation index (P.I.) are shown as average number of apoptotic nuclei per HPF and number of mitotic figures per HPF. S-DNA histogram area was measured by CAS 200 system in arbitrary units. Single strand-DNA mAb area was measured in digital images by Optimas 6.5 and ss-DNA mAb density was measured in arbitrary units of photomultiplier scanner.

Pre-drug treated@ Post-drug treated#	Sodium MRI signal intensityd		Histology (in HPF)	A.I. (KI-67)	P.I. (in HPF)	S-DNA (histogram)	ss-DNA mAb (density units)
Tumor feature	IR	SQ	(CAS)
Control (n = 41)	4.25 ± 1.0	5.27 ± 2.0	-	-	-	-	-
Sham (n = 40)	4.30 ± 0.2	5.38 ± 1.0
Tumor area(mm2;n = 16)@	4.56 ± 0.30	4.67 ± 0.30	4.49 ± 0.2	-	-	3.6 ± 0.2	4.2 ± 0.2
Tumor area(mm2;n = 3)#	4.60 ± 0.29	4.61 ± 0.26	4.42 ± 0.3	-	-	3.5 ± 0.3	4.3 ± 0.3
IC/EC space@	60–70		65–76	-	-	-	-
IC/EC space#	80–95		60–70	-	-	-	-
Necrosis*(squares)@	gray		56 ± 32	-	270	M-DNA	-
Necrosis*(squares)#	bright		50 ± 23	-	120	M-DNA	-
Viable**(squares)@	dark		65 ± 21	-	-	-	-
Viable**(squares)#	dark		76 ± 11	-	-	-	-
Apoptosis***(nuclei)@	bright		40 ± 12	150	-	S-DNA	159 ± 12
Apoptosis***(nuclei)#	bright		50 ± 13	160	-	M or S-DNA	129 ± 20
Cyst****(size in μm)@	gray		120 ± 29	-	-	-	-
Cyst****(size in μm)#	gray		80 ± 22	-	-	-	-